β-Lactam type molecular scaffolds for antiproliferative activity: Synthesis and cytotoxic effects in breast cancer cells

References

• JI MacGregor, and VC Jordan. (1998). Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50 (2):151–196.
   Google Scholar
• VC Jordan. (2003). Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 46 (6):883–908.
   Google Scholar
• VC Jordan. (2003). Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 46 (7):1081–1111.
   Google Scholar
• EA Ariazi, JL Ariazi, F Cordera, and VC Jordan. (2006). Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6 (3):181–202.
   Google Scholar
• TA Grese, S Cho, DR Finley, AG Godfrey, CD Jones, CW Lugar3rd, MJ Martin, K Matsumoto, LD Pennington, MA Winter, MD Adrian, HW Cole, DE Magee, DL Phillips, ER Rowley, LL Short, AL Glasebrook, and HU Bryant. (1997). Structure–activity relationships of selective estrogen receptor modulators: Modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem 40 (2):146–167.
   Google Scholar
• B Fisher, JP Costantino, DL Wickerham, CK Redmond, M Kavanah, WM Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins, M Daly, S Wieand, E Tan-Chiu, L Ford, and N Wolmark. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90 (18):1371–1388.
   PubMed Web of Science ®Google Scholar
• S Ahmed. (1998). Review of the molecular modelling studies of the cytochrome P-450 estrogen synthetase enzyme, aromatase. Drug Des Discov 15 (4):239–252.
   Google Scholar
• JF Robertson. (2001). Faslodex (ICI 182, 780), a novel estrogen receptor downregulator–future possibilities in breast cancer. J Steroid Biochem Mol Biol 79 (1–5):209–212.
   Google Scholar
• V Stearns, NE Davidson, and DA Flockhart. (2004). Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4 (3):143–153.
   Google Scholar
• J Jensen, JW Kitlen, P Briand, F Labrie, and AE Lykkesfeldt. (2003). Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J Steroid Biochem Mol Biol 84 (4):469–478.
   Google Scholar
• I Kijima, T Itoh, and S Chen. (2005). Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. J Steroid Biochem Mol Biol 97 (4):360–368.
   Google Scholar
• AM Brodie, Q Lu, BJ Long, A Fulton, T Chen, N Macpherson, PC DeJong, MA Blankenstein, JW Nortier, PH Slee, J van de Ven, JM van Gorp, JR Elbers, ME Schipper, GH Blijham, and JH Thijssen. (2001). Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79 (1-5):41–47.
   Google Scholar
• JA Gustafsson. (1999). Estrogen receptor beta–a new dimension in estrogen mechanism of action. J Endocrinol 163 (3): 379–383.
   Google Scholar
• ST Pearce, and VC Jordan. (2004). The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 50 (1):3–22.
   Google Scholar
• A Bardin, N Boulle, G Lazennec, F Vignon, and P Pujol. (2004). Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11 (3): 537–551.
   Google Scholar
• AK Shiau, D Barstad, PM Loria, L Cheng, PJ Kushner, DA Agard, and GL Greene. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 (7):927–937.
   PubMed Web of Science ®Google Scholar
• AM Brzozowski, AC Pike, Z Dauter, RE Hubbard, T Bonn, O Engstrom, L Ohman, GL Greene, JA Gustafsson, and M Carlquist. (1997). Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (6652):753–758.
   PubMed Web of Science ®Google Scholar
• AC Pike, AM Brzozowski, RE Hubbard, T Bonn, AG Thorsell, O Engstrom, J Ljunggren, JA Gustafsson, and M Carlquist. (1999). Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18 (17):4608–4618.
   PubMedGoogle Scholar
• YL Wu, X Yang, Z Ren, DP McDonnell, JD Norris, TM Willson, and GL Greene. (2005). Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 18 (4): 413–424.
   Google Scholar
• AC Pike, AM Brzozowski, J Walton, RE Hubbard, AG Thorsell, YL Li, JA Gustafsson, and M Carlquist. (2001). Structural insights into the mode of action of a pure antiestrogen. Structure 9 (2):145–153.
   Google Scholar
• DG Lloyd, RB Hughes, DM Zisterer, DC Williams, C Fattorusso, B Catalanotti, G Campiani, and MJ Meegan. (2004). Benzoxepin-derived estrogen receptor modulators: A novel molecular scaffold for the estrogen receptor. J Med Chem 47 (23):5612–5615.
   Google Scholar
• DG Lloyd, HM Smith, T O' Sullivan, DM Zisterer, and MJ Meegan. (2005). Synthesis, structure–activity realtionships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators. Med Chem 1 (4): 335–353.
   Google Scholar
• MJ Meegan, I Barrett, J Zimmermann, AJ Knox, DM Zisterer, and DG Lloyd. (2007). Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: Synthesis and antagonistic effects in breast cancer cells. J Enzyme Inhib Med Chem 22 (5):655–666.
   Google Scholar
• DG Lloyd, HM Smith, T O'Sullivan, AS Knox, DM Zisterer, and MJ Meegan. (2006). Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: Synthesis, structure–activity relationships and molecular modeling study for flexible estrogen receptor antagonists. Med Chem 2 (2):147–168.
   Google Scholar
• AJ Knox, MJ Meegan, and DG Lloyd. (2006). Estrogen receptors: Molecular interactions, virtual screening and future prospects. Curr Top Med Chem 6 (3):217–243.
   Google Scholar
• S Kim, JY Wu, ET Birzin, K Frisch, W Chan, LY Pai, YT Yang, RT Mosley, PM Fitzgerald, N Sharma, J Dahllund, AG Thorsell, F DiNinno, SP Rohrer, JM Schaeffer, and ML Hammond. (2004). Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators. J Med Chem 47 (9):2171–2175.
   Google Scholar
• L Gennari. (2006). Lasofoxifene: A new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc) 42 (6):355–367.
   Google Scholar
• SR Stauffer, YR Huang, ZD Aron, CJ Coletta, J Sun, BS Katzenellenbogen, and JA Katzenellenbogen. (2001). Triarylpyrazoles with basic side chains: Development of pyrazole-based estrogen receptor antagonists. Bioorg Med Chem 9 (1): 151–161.
   Google Scholar
• J Renaud, SF Bischoff, T Buhl, P Floersheim, B Fournier, M Geiser, C Halleux, J Kallen, H Keller, and P Ramage. (2005). Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure–activity relationship of ERalpha-selective tetrahydroisoquinoline ligands. J Med Chem 48 (2):364–379.
   Google Scholar
• F Labrie, C Labrie, A Belanger, J Simard, S Gauthier, V Luu-The, Y Merand, V Giguere, B Candas, S Luo, C Martel, SM Singh, M Fournier, A Coquet, V Richard, R Charbonneau, G Charpenet, A Tremblay, G Tremblay, L Cusan, and R Veilleux. (1999). EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 69 (1–6):51–84.
   Google Scholar
• BK Banik, and FF Becker. (2001). Synthesis, electrophilic substitution and structure–activity relationship studies of polycyclic aromatic compounds towards the development of anticancer agents. Curr Med Chem 8 (12):1513–1533.
   Google Scholar
• BK Banik, FF Becker, and I Banik. (2004). Synthesis of anticancer beta-lactams: Mechanism of action. Bioorg Med Chem 12 (10):2523–2528.
   Google Scholar
• EL Setti, D Davis, JW Janc, DA Jeffery, H Cheung, and W Yu. (2005). 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity. Bioorg Med Chem Lett 15 (5):1529–1534.
   Google Scholar
• G Veinberg, M Vorona, I Shestakova, I Kanepe, O Zharkova, R Mezapuke, I Turovskis, I Kalvinsh, and E Lukevics. (2000). Synthesis and antitumor activity of selected 7-alkylidene substituted cephems. Bioorg Med Chem 8 (5):1033–1040.
   Google Scholar
• G Veinberg, I Shestakova, M Vorona, I Kanepe, and E Lukevics. (2004). Synthesis of antitumor 6-alkylidenepenicillanate sulfones and related 3-alkylidene-2-azetidinones. Bioorg Med Chem Lett 14 (1):147–150.
   Google Scholar
• DA Burnett. (2004). Beta-lactam cholesterol absorption inhibitors. Curr Med Chem 11 (14):1873–1887.
   Google Scholar
• RM Adlington, JE Baldwin, GW Becker, B Chen, L Cheng, SL Cooper, RB Hermann, TJ Howe, W McCoull, AM McNulty, BL Neubauer, and GJ Pritchard. (2001). Design, synthesis, and proposed active site binding analysis of monocyclic 2-azetidinone inhibitors of prostate specific antigen. J Med Chem 44 (10):1491–1508.
   Google Scholar
• JC Sutton, SA Bolton, ME Davis, KS Hartl, B Jacobson, A Mathur, ML Ogletree, WA Slusarchyk, R Zahler, SM Seiler, and GS Bisacchi. (2004). Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett 14 (9):2233–2239.
   Google Scholar
• M Masui, and H Ohmuri. (1972). Aniodic oxidation of Schiff bases. Part I. Oxidation of N-benzylidene-p-anisidines in acetonitrile. J Chem Soc Perkin Trans 2 1882–1886.
   Google Scholar
• KS Balachandran, I Bhatnagar, and MV George. (1968). Oxidation by metal oxides. IV. Oxidation of organic compounds using nickle peroxide. J Org Chem 33:3891–3895.
   Google Scholar
• C Palomo, FP Cossio, A Arrieta, JM Odriozola, M Oiarbide, and JM Ontoria. (1989). The Reformatsky type reaction of Gilman and Speeter in the preparation of valuable beta-lactams in carbapenem synthesis–scope and synthetic utility. J Org Chem 54 (24):5736–5745.
   Google Scholar
• HH Otto, and R Mayrhofer. (1983). Stereochemistry of dehydration and halogenation of alpha-R-star and alpha-S-star isomeric 3-(alpha-hydroxybenzyl)-1,4-diphenyl-2-azetidinones. Liebigs Ann Chem (7):1162–1168.
   Google Scholar
• HH Otto, R Mayrhofer, and HJ Bergmann. (1983). Synthesis and stereochemistry of 3-(a-hydroxybenzyl)-1,4-diphenyl-2-azetidinones. Liebigs Ann Chem (7):1152–1161.
   Google Scholar
• C Palomo, JM Aizpurua, I Ganboa, and M Oiarbide. (2004). Asymmetric synthesis of beta-lactams through the Staudinger reaction and their use as building blocks of natural and nonnatural products. Curr Med Chem 11 (14):1837–1872.
   Google Scholar
• CR Overk, KW Peng, RT Asghodom, I Kastrati, DD Lantvit, Z Qin, J Frasor, JL Bolton, and GR Thatcher. (2007). Structure–activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. Chem Med Chem 2 (10):1520–1526.
   Google Scholar
• JA McKie, SS Bhagwat, H Brady, M Doubleday, L Gayo, M Hickman, RK Jalluri, S Khammungkhune, A Kois, D Mortensen, N Richard, J Sapienza, G Shevlin, B Stein, and M Sutherland. (2004). Lead identification of a potent benzopyranone selective estrogen receptor modulator. Bioorg Med Chem Lett 14 (13):3407–3410.
   Google Scholar
• BA Littlefield, E Gurpide, L Markiewicz, B McKinley, and RB Hochberg. (1990). A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: Estrogenic action of delta 5 adrenal steroids. Endocrinology 127 (6):2757–2762.
   Google Scholar
• V Sobolev, A Sorokine, J Prilusky, EE Abola, and M Edelman. (1999). Automated analysis of interatomic contacts in proteins. Bioinformatics 15 (4):327–332.
   Google Scholar